Mode
Text Size
Log in / Sign up

Systemic Inflammatory Response Syndrome

Subtypes of Systemic Inflammatory Response Syndrome

Sepsis 81 Septic Shock 17 Neonatal Sepsis 8 Bloodstream infections 3 Candidemia 2 Septicemia 2 Cytokine release syndrome 1 Fungemia 1

107 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Systemic Inflammatory Response Syndrome

6 trials tracked for Systemic Inflammatory Response Syndrome: 1 in phase 3 or 4.

6Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 2 2 Phase 1 1 Other / NA 2
  1. Phase 4 High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy Completed
  2. Phase 2 A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS Completed
  3. Phase 2 CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS Completed
  4. Phase 1 Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum Completed
  5. N/A PPV to Guide Fluid Management in the PICU Completed
  6. N/A Bacterial Translocation Markers as Predictors of Infectious and Inflammatory Complications in Acute Bowel Obstruction Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Systemic Inflammatory Response Syndrome: current evidence & treatments

Systemic inflammatory response syndrome (SIRS) is a critical condition often associated with sepsis. Diagnostic tools for sepsis-related complications show variable performance: Cystatin C demonstrates good diagnostic accuracy for sepsis-associated acute kidney injury with an AUC of 0.88 1, while IL-27 outperforms CRP for neonatal sepsis diagnosis (AUC 0.92) 16. In low- and middle-income countries, qSOFA has moderate discrimination (AUROC 0.74) with low sensitivity (0.51) but high specificity (0.83), whereas SIRS has higher sensitivity (0.86) but lower specificity (0.32) 13. Prediction models for mortality in sepsis show moderate performance (pooled AUC 0.794) 2, and models for ARDS occurrence in sepsis have test-phase AUC 0.749 3.

Management strategies emphasize source control and antibiotic stewardship 8, with antibiotic stewardship bundles aiming to reduce antibiotic use in NICUs 7. Immunomodulatory therapies show promise: ulinastatin reduces all-cause mortality (RR 0.37) 17, and interleukin-7 improves lymphocyte counts but not mortality in sepsis 11. Procalcitonin-guided care did not affect early antibiotic initiation but lowered 28-day mortality 25. Long-term outcomes for sepsis survivors are poor, with 44% readmission at 1 year and 42.3% mortality at 5 years, along with persistent cognitive, physical, and psychological impairments 24.

Latest findings

AI-generated synthesis of 11 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

All Systemic Inflammatory Response Syndrome Articles